Document Detail

Galiximab: a review.
MedLine Citation:
PMID:  20092425     Owner:  NLM     Status:  MEDLINE    
IMPORTANCE OF THE FIELD: A significant number of patients relapse or do not respond to rituximab due to intrinsic or acquired resistance. Hence, mAbs targeting other cell surface antigens on B-cell lymphomas are being studied. CD80 is a glycoprotein expressed on Hodgkin's lymphoma, mature B-cell lymphomas and immunoeffector cells which may have T-regulatory, in addition to direct antitumor activity. CD80 serves as an attractive target in the continued development of mAbs against lymphoma. AREAS COVERED IN THIS REVIEW: Preclinical studies with galiximab, an anti-CD80 primatized mAb, have been encouraging and have demonstrated antitumor activity against various B-cell lymphoma models, both as a single agent as well as in combination with rituximab. Data were reviewed from a PubMed literature search from 1975 to 2009 and also included a review of abstracts from published proceedings of annual meetings from the American Society of Hematology and International Conference of Malignant Lymphoma, Lugano. WHAT THE READER WILL GAIN: Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab. An update of currently available clinical data will be presented. TAKE HOME MESSAGE: Data from completed clinical trials are promising and galiximab is being studied in both upfront and relapsed settings with the potential of being incorporated into the future treatment of B-cell lymphoma.
Seema Bhat; Myron S Czuczman
Related Documents :
10898565 - Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens.
12469325 - The proto-oncogene bcl-6 in normal and malignant b cell development.
17607925 - Individualized target therapy of malignant lymphomas: an outlook.
20181615 - In vivo targeting of b-cell lymphoma with glycan ligands of cd22.
23377265 - Treatment with small molecules is an important milestone towards the induction of pluri...
18397745 - Illuminating the black box of reprogramming.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  10     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  451-8     Citation Subset:  IM    
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antigens, CD80 / immunology
Antineoplastic Agents / therapeutic use*
Lymphoma, Non-Hodgkin / drug therapy*,  immunology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD80; 0/Antineoplastic Agents; 357613-77-5/galiximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Farletuzumab in epithelial ovarian carcinoma.
Next Document:  Resource implications and budget impact of managing cow milk allergy in the UK.